EISAI CO. LTD/ JP3160400002 /
| 2024-05-29 12:06:43 PM | Chg. -0.36 | Volume | Bid1:30:56 PM | Ask1:30:56 PM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 39.44EUR | -0.90% | 210 Turnover: 8,262.06 |
39.10Bid Size: 129 | 39.52Ask Size: 128 | 11.28 bill.EUR | - | - |
GlobeNewswire
3:00 AM
BIOGEN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Fil...
GlobeNewswire
05-28
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen...
GlobeNewswire
05-28
Numab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-Owned Subsidiary Yellow Jersey ...
GlobeNewswire
05-25
BIIB INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with ...
GlobeNewswire
05-25
BIOGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Again...
GlobeNewswire
05-24
Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradio...
GlobeNewswire
05-24
BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Sub...
GlobeNewswire
05-23
Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Biogen, Inc. (BIIB...
GlobeNewswire
05-23
BIIB INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with Sub...
GlobeNewswire
05-22
Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0...
GlobeNewswire
05-15
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Su...
GlobeNewswire
05-14
Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinic...
GlobeNewswire
04-29
BeyondSpring Provides Business Update and Reports Year End 2023 Financial Results
GlobeNewswire
03-29
Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development
GlobeNewswire
03-27
Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regula...
GlobeNewswire
03-12
How Do Companies Avert Further Frustration among Neurologists Due to Relyvrio’s (Amylyx) Phase 3 Fai...
GlobeNewswire
03-04
Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (...
GlobeNewswire
02-28
PulseSight Therapeutics Launches to Advance Non-viral Gene Therapies with Disruptive Minimally-Invas...
GlobeNewswire
02-22
Neurologists Report Frustration with Efficacy and Logistical Issues Around Eisai/Biogen’s Leqembi, A...
GlobeNewswire
01-22
PDS Biotech Announces Retirement of Lauren V. Wood, M.D., and Appointment of Kirk V. Shepard, M.D., ...
GlobeNewswire
2023-12-19
Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European C...
GlobeNewswire
2023-12-07
TScan Therapeutics Appoints R. Keith Woods to its Board of Directors, Bringing Expertise in Commerci...
